Eun Kyung Cho

Eun Kyung Cho

Auto-generated profile, based on publicly available information

Eun Kyung Cho

11Division of Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
MKMinsun Kang
Minsun Kang
YCYong Soon Chun
Yong Soon Chun
HPHeung Kyu Park
Heung Kyu Park
ECEun Kyung Cho
Eun Kyung Cho
JJJaehun Jung
Jaehun Jung
YKYunyeong Kim
Yunyeong Kim
Kang M, et al. Ann Surg Treat Res. 2022 Feb;102(2):73-82. https://doi.org/10.4174/astr.2022.102.2.73

20 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SJSeung Hyuck Jeon
Seung Hyuck Jeon
KSKoung Jin Suh
Koung Jin Suh
SJSungmin Jung
Sungmin Jung
MJMinwoo Jeon
Minwoo Jeon
HJHo Cheol Jang
Ho Cheol Jang
ESEui-Cheol Shin
Eui-Cheol Shin
Purpose: PD-1/PD-L1 blockade modulates the responses of T cells, including regulatory T cells (Treg). Understanding the changes of Treg upon PD-1/PD-L1 blockade in patients with cancer and their association with therapeutic response will provide clues about the mechanisms underlying resistance to treatment. Experimental Design: Peripheral blood samples were acquired before and at 1 week following treatment from 65 patients [triple-negative (TN), n = 35; luminal, n = 30] enrolled in the KORNELIA phase II trial, which evaluated the efficacy of chemoimmunotherapy combining nivolumab and eribulin in patients with HER2-negative breast cancer. The immunophenotype of circulating immune cells was analyzed by flow cytometry. T-cell receptor sequencing was used to track the clonotypes of circulating Treg in relation to the tumor-related clonotypes. Results: In both breast cancer subtypes, chemoimmunotherapy increased the proportion of circulating Treg as well as their proliferative response. Notably, we observed an increased frequency of the circulating Treg population with tumor-related clonotypes after treatment in triple-negative breast cancer (TNBC). Moreover, increased proliferation of circulating Treg was associated with poor response to treatment, only in TNBC. This association between circulating Treg proliferation and poor clinical response was further supported by the analysis of publicly available single-cell transcriptomic data from patients with TNBC. A Treg-based biomarker predicted both clinical response and survival outcomes in TNBC. Conclusions: Our results indicate that the proliferation and expansion of tumor-related clonotypes among circulating Treg are related to chemoimmunotherapy resistance, particularly in TNBC.


3 November 2025
Verified
Other
Open access
SJSeung Hyuck Jeon
Seung Hyuck Jeon
KSKoung Jin Suh
Koung Jin Suh
SJSungmin Jung
Sungmin Jung
MJMinwoo Jeon
Minwoo Jeon
HJHo Cheol Jang
Ho Cheol Jang
ESEui-Cheol Shin
Eui-Cheol Shin
Table S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer

3 November 2025
Verified
Other
Open access
SJSeung Hyuck Jeon
Seung Hyuck Jeon
KSKoung Jin Suh
Koung Jin Suh
SJSungmin Jung
Sungmin Jung
MJMinwoo Jeon
Minwoo Jeon
HJHo Cheol Jang
Ho Cheol Jang
ESEui-Cheol Shin
Eui-Cheol Shin
Table S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer